DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care
21. November 2024 09:00 ET
|
DANNCE.AI
DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform.
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
14. November 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein...
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
05. November 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease (PD) on track to report interim safety and...
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
06. August 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Announced exclusive option and license agreement with Takeda for ACI-24.060 on May 13 for $100 million upfront...
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
13. Mai 2024 06:05 ET
|
AC Immune SA
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for...
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
14. März 2024 07:00 ET
|
AC Immune SA
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2ACI-7104.056 VacSYn Phase 2 trial in...
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
22. Februar 2024 07:00 ET
|
AC Immune SA
AC Immune Announces Upcoming Presentations at AD/PD™ 2024 Multiple presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2024)Andrea Pfeifer, Ph.D., CEO to...
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
03. Januar 2024 08:10 ET
|
AC Immune SA
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD trial of ACI-24.060 completed enrollment of cohorts 1 and 2 and...
NRG Therapeutics Awarded Second $500K Grant from The Michael J. Fox Foundation to Further Progress Parkinson’s Programme
22. Februar 2023 04:00 ET
|
NRG Therapeutics Limited
STEVENAGE, United Kingdom, Feb. 22, 2023 (GLOBE NEWSWIRE) -- NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been...
IGC to Present at the RHK 2022 Disruptive Growth Conference
30. November 2022 11:19 ET
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”) today announced that Ram Mukunda, Chief Executive Officer, will be...